Javier Pinilla-Ibarz, MD, PhD, is an associate member of the malignant hematology and immunology program at the H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz also is an associate professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida. Dr. Pinilla-Ibarz is leading the chronic leukemia program at Moffitt, and its principal interest in the clinic is patients with myeloid and lymphoid chronic leukemia. In this regard, Dr. Pinilla-Ibarz has participated in multiple clinical trials involving tyrosine kinase inhibitors, some of them now approved. Dr. Pinilla-Ibarz is also the director of immunotherapy for malignant hematology. He has been involved in developing new immunotherapeutic approaches in hematological malignancies. Other research areas of interest include the epigenetic immune regulation in CLL and ER stress pathways, as well as the role of the bone marrow microenvironment in mediating resistance to TKIs and the interaction of TKIs with the immune system. Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association and the American Society of Clinical Oncology and other national/international meetings. His work has been published in journals including Blood, Nature Immunology, Seminars of Hematology and Leukemia. He has also authored multiple book chapters. Dr. Pinilla-Ibarz received both his MD and PhD from the University of Zaragoza, School of Medicine, Spain. He completed his residency in medicine and a fellowship in Hematology at La Paz University Hospital in Madrid, Spain and after he moved to the US he also completed a residency in Internal Medicine at Cornell Medical Center and a fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center in New York City.